Bempedoic acid

Bempedoic acid has been studied in 91 papers since 2021: 7 trials and 22 observational studies in people, 2 in animals, 57 reviews; 74 in the past year. It is an approved medicine.

InterventionApproved 2020

91 papers study it8 more mention it63 findingsUpdated

PubChemChEBI

27 new papers in 30 daysSee all 98 papers on bempedoic acid

At a glance

Bempedoic acid reduces cardiovascular events and LDL cholesterol in human trials, reproduced by independent labs, but increases hyperuricemia in hypercholesterolemia. An observational comparison with ezetimibe shows no clear cardiovascular-event link in statin-intolerant patients with cardiovascular-kidney-metabolic syndrome receiving GLP-1 receptor agonists for secondary prevention. Some authors work at companies, and a human paper declares ties to developer Organon.

63 findings in 31 papers from 2021 to 2026, 16 of them since May 2026

Independent labs found the same change in people. 24 independent labs in 10 countries; 117 trials, 58 about aging, 67 with no results posted.

“LDL-C fell by 24.3 % (95 % CI −27.8 to −20.9)”
Bempedoic Acid Lowers LDL-C and Reduces Risk of Major Cardiovascular Events in Hypercholesterolemia: Meta-Analysis of 13 Randomized Controlled TrialsAHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4372102

2 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 24 independent labs in 10 countries
  • 2 findings against
  • 117 trials, 58 about aging, 67 with no results posted
  • Funders: Charite - Universitaetsmedizin Berlin and 8 more
  • 25 of 52 findings with company ties
  • 68 of 117 trials sponsored by its developers
  • Human trial7
  • Humans21
  • Animals2
  • In silico3

8 studies gave bempedoic acid to people and measured what changed.

What changedDesignPeopleSource

down: Lowers the risk of major adverse limb events36%

down: Decreases total major adverse limb events2.9 with bempedoic acid versus 4.0 with placebo

down: Lowers the risk of major adverse cardiovascular events or major adverse limb eventsHR, 0.87 [95% CI, 0.80–0.95]

Randomized trialmedian of 40.6 months13,970 peopleBoth18 to 85 years of agePatients 18 to 85 years of age with history of or at high risk of cardiovascular diseases who were not able to take recommended statin treatment because of intoleranceCirculation, Aug 18, 2026

down: Decreases LDL-C−22.75%

up: Increases uric acid+0.96 mg/dL

Treated cohortmedian follow-up duration of 28 weeks (IQR 23–47 weeks)125 people79.2% were malemean age 62.4 ± 10.1 yearsPatients with CCS, aged ≥18 years, with LDL-C levels ≥ 55 mg/dL despite at least 8 weeks of stable intensive lipid-lowering therapyJournal of clinical medicine, Aug 5, 2026

down: Decreases LDL cholesterol-18.02% (95% CI, -18.83 to -17.21)

Review of trials6,025 people pooledOn top of statin therapyJournal of clinical lipidology, Feb 26, 2026

down: Decreases major adverse cardiovascular events

Randomized trialmedian follow-up 40.6 months13,970 people66 ±9 yearsOlder adults; in patients with elevated steatosis scoresEuropean journal of preventive cardiology, Feb 16, 2026

down: Decreases LDL-C-19% (IQR -36.4% to -3.6%, p < 0.01)

down: Decreases C-reactive protein-34.0% (p < 0.01)

Trial12 weeks180 peoplePatient cohortsmedRxiv, Feb 9, 2026

What did studies of bempedoic acid find?

23

Studies of bempedoic acid measured 23 outcomes; the most studied are LDL-C (8 studies), LDL cholesterol (6) and uric acid (2).

LDL-C

downin humans8−23%

8 studies
  1. Bempedoic acid decreases LDL-C in humans (−22.75%).

    “The addition of BA resulted in a significant reduction in LDL-C levels, from 71.90 ± 18.03 mg/dL to 55.54 ± 14.23 mg/dL (absolute reduction: 16.36 mg/dL; relative reduction: −22.75%; p < 0.001).”

    Human trialmedian follow-up duration of 28 weeks (IQR 23–47 weeks)n = 118

    Bempedoic Acid in Patients with Chronic Coronary Syndrome Not Achieving LDL Targets Despite Intensive Therapy: A Real-World Study from Spain

    Journal of clinical medicine

  2. Bempedoic acid decreases LDL-C in humans (-19% (IQR -36.4% to -3.6%, p < 0.01)).

    “The median percentage change in LDL-C from baseline to week 12 was -19% (interquartile range [IQR]: -36.4% to -3.6%), decreasing from 117.5 to 92 mg/dL (p < 0.01).”

    Human trial12 weeksn = 180

    Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients with Hypercholesterolemia - A Pragmatic Phase IV Study (CLEAR Taiwan Study)

    medRxivPreprint

  3. Bempedoic acid decreases LDL-C in humans (hypercholesterolemia) (-24.3% (95% CI -27.8 to -20.9)).

    “LDL-C fell by 24.3 % (95 % CI −27.8 to −20.9)”

    Human trialhypercholesterolemia

    Bempedoic Acid Lowers LDL-C and Reduces Risk of Major Cardiovascular Events in Hypercholesterolemia: Meta-Analysis of 13 Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

  4. Bempedoic acid is linked with lower LDL-C in humans (mean reduction 1.05 mmol/L (SD 0.15)).

    “Mean LDL-C reduction across the cohort was 1.05 mmol/L (SD 0.15)”

    Humans

    Real-world use of bempedoic acid for ASCVD risk reduction in a rural UK primary care practice: Analysing trends in LDL-C reduction, adherence, and ESC target attainment

    ESC Congress 2026 abstract

  5. Bempedoic acid is linked with lower LDL-C in humans (-22.8% (-16.36 mg/dL)).

    “BA reduced LDL-C by 22.8% (-16.36 mg/dL; p < 0.001), enabling 48.3% of patients to achieve LDL-C < 55 mg/dL.”

    Humansin chronic coronary syndrome patients with LDL-C ≥ 55 mg/dL despite stable intensive lipid-lowering therapy180 mg/daymedian follow-up of 28 weeksn = 118

    Bempedoic Acid in Patients with Chronic Coronary Syndrome Not Achieving LDL Targets Despite Intensive Therapy: A Real-World Study from Spain

    Journal of clinical medicine

  6. Bempedoic acid is linked with lower LDL-C in humans (21%, p < 0.0001).

    “By 3 months, BA (21%) and BA + EZE (33%, p < 0.0001 for both) were associated with significant reductions in median LDL-C levels.”

    Humans3 monthsn = 900

    LDL-C lowering in patients treated with bempedoic acid in a real-world cohort

    Atherosclerosis plus

  7. Bempedoic acid is linked with lower LDL-C in humans (compared with baseline LDL-C of 138 mg/dl) (88 vs 138 mg/dl baseline at 3 months; 92 mg/dl at 1 year).

    “BA significantly lowered LDL-C levels at 3 months (88mg/dl +/- 32) (p <0.001)”

    Humanscompared with baseline LDL-C of 138 mg/dlup to 1 year

    SAT-263 Access to Bempedoic Acid - A Real World Assessment in an Academic Clinical Practice

    ENDO 2025 abstract

  8. Bempedoic acid decreases LDL-C in high- and very-high-risk individuals unable or unwilling to take statins.

    “Bempedoic acid emerged as a generally safe, efficient, and cost-effective strategy to lower LDL-C and cardiovascular risk”

    Reviewin high- and very-high-risk individuals unable or unwilling to take statins

    Bempedoic Acid: From Guidelines to the Real World

    Journal of lipid and atherosclerosis

  9. Bempedoic acid decreases LDL-C in patients with elevated LDL-C.

    “In domestic and international clinical studies, bempedoic acid reduced LDL-C levels in patients with elevated LDL-C, regardless of their response to statin therapy.”

    Reviewin patients with elevated LDL-C

    Pharmacological properties and clinical efficacy of bempedoic acid (NEXLETOL® tablets 180 mg) for the treatment of hypercholesterolemia

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica

More on LDL-C

LDL cholesterol

downin humans6

6 studies
  1. Bempedoic acid decreases LDL cholesterol in humans (on top of statin therapy) (-18.02% (95% CI, -18.83 to -17.21)).

    “bempedoic acid produced a reduction of -18.02% (95% CI, -18.83 to -17.21)”

    Human trialon top of statin therapy

    Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis

    Journal of clinical lipidology

  2. Bempedoic acid decreases LDL cholesterol in humans (monotherapy in statin-intolerant patients without baseline lipid lowering therapies) (-20.6% (95% CI, -21.7 to -19.6%)).

    “Bempedoic acid monotherapy lowered LDL-C by -20.6% (95% CI, -21.7 to -19.6%) compared with placebo at 6 months.”

    Human trialmonotherapy in statin-intolerant patients without baseline lipid lowering therapies180 mg6 monthsn = 8,217

    Bempedoic acid monotherapy, LDL cholesterol and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial

    AHA Scientific Sessions 2025 abstract

  3. Bempedoic acid is linked with lower LDL cholesterol in humans (On stable background lipid-lowering therapy) (Median LDL-C reduction 20.1% (IQR 0.0; 39.4)).

    “BA alone (20.1%, IQR 0.0; 39.4)”

    HumansOn stable background lipid-lowering therapyMedian follow-up of 6.5 monthsn = 108

    Real-world efficacy of bempedoic acid: early insights from the BEMPENET Italian Registry

    ESC Congress 2026 abstract

  4. Bempedoic acid is linked with lower LDL cholesterol in humans (added to existing lipid-lowering therapy; before-and-after comparison) (mean reduction 31.8 mg/dL; mean patient-level change -17.5%).

    “The addition of bempedoic acid significantly reduced LDL-C levels from a mean of 133.6 mg/dL at baseline to 101.8 mg/dL after 3 months (p < 0.001).”

    Humansadded to existing lipid-lowering therapy; before-and-after comparisonabout 3 monthsn = 641

    Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study

    Lipids in health and disease

  5. Bempedoic acid is linked with lower LDL cholesterol in humans (-28.8% (121.3 to 86.5 mg/dL)).

    “BA significantly reduced total cholesterol (207.4-167.8 mg/dL; -19.1%) and LDL-C (121.3-86.5 mg/dL; -28.8%)”

    Humans3 monthsn = 814

    Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort

    Journal of clinical lipidology

  6. Bempedoic acid decreases LDL cholesterol in humans (patients with dyslipidemia).

    “Currently available treatment options to lower LDL-C with proven cardiovascular benefit include statins, ezetimibe, bempedoic acid, and PCSK9 antibodies.”

    Reviewpatients with dyslipidemia

    Choosing the Right Non-Statin Therapy for the Right Patient - How To Sequence Advanced Lipid-Lowering Therapies

    Current atherosclerosis reports

More on LDL cholesterol

Uric acid

upin humans2+11%

2 studies
  1. Bempedoic acid increases uric acid in humans (+0.96 mg/dL).

    “Treatment with BA was associated with an increase in serum uric acid levels (+0.96 mg/dL, p < 0.001), without clinical gout flares.”

    Human trialmedian follow-up duration of 28 weeks (IQR 23–47 weeks)n = 118

    Bempedoic Acid in Patients with Chronic Coronary Syndrome Not Achieving LDL Targets Despite Intensive Therapy: A Real-World Study from Spain

    Journal of clinical medicine

  2. Bempedoic acid is linked with higher uric acid in chronic coronary syndrome patients receiving intensive lipid-lowering therapy.

    “BA was well tolerated, with a modest increase in uric acid levels but no gout events and a high treatment persistence rate (94.4%).”

    Humansin chronic coronary syndrome patients receiving intensive lipid-lowering therapy180 mg/daymedian follow-up of 28 weeksn = 118

    Bempedoic Acid in Patients with Chronic Coronary Syndrome Not Achieving LDL Targets Despite Intensive Therapy: A Real-World Study from Spain

    Journal of clinical medicine

  3. Bempedoic acid is linked with higher uric acid in humans (+11.4%).

    “Uric acid increased (+11.4%; P < 0.001).”

    Humans

    Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort

    Journal of clinical lipidology

More on Uric acid

Major adverse cardiovascular events

no changein humans1downin humans1

2 studies
  1. Bempedoic acid decreases major adverse cardiovascular events in patients with elevated steatosis scores.

    “Bempedoic acid reduced MACE4 risk, with an additional benefit in patients with elevated steatosis scores.”

    Human trialin patients with elevated steatosis scoresmedian follow-up 40.6 monthsn = 13,970

    Effect of bempedoic acid on cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease

    European journal of preventive cardiology

  2. Bempedoic acid was not clearly linked with major adverse cardiovascular events in humans (MACE-3 incidence: 7.9% versus 9.2%; p=0.338).

    “bempedoic acid was not associated with a significant reduction in MACE compared with ezetimibe”

    HumansCompared with ezetimibe in statin-intolerant patients with cardiovascular-kidney-metabolic syndrome receiving GLP-1 receptor agonists for secondary prevention1 year

    Bempedoic Acid versus Ezetimibe for Secondary Prevention in Statin-Intolerant Patients with Cardiovascular-Kidney-Metabolic Syndrome Taking Glucagon-Like Peptide-1 Receptor Agonists

    AHA Scientific Sessions 2026 abstract

Mortality

downin humans1no changein humans1RR 0.62–0.87

2 studies
  1. Bempedoic acid showed no clear effect on mortality in humans (hypercholesterolemia) (RR 0.87 (95% CI 0.53–1.43)).

    “while CV mortality was unchanged (RR 0.87, 95 % CI 0.53–1.43)”

    Human trialhypercholesterolemia

    Bempedoic Acid Lowers LDL-C and Reduces Risk of Major Cardiovascular Events in Hypercholesterolemia: Meta-Analysis of 13 Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

  2. Bempedoic acid is linked with lower mortality in humans (statin-intolerant hyperlipidemia vs ezetimibe) (2.0% vs 3.3%; RR 0.62, 95% CI 0.55-0.70; HR 0.56, 0.50-0.63; P<0.001).

    “bempedoic acid was associated with lower 3-year all-cause mortality (2.0% vs 3.3%; RR 0.62, 95% CI 0.55-0.70; HR 0.56, 0.50-0.63; P<0.001)”

    Humansstatin-intolerant hyperlipidemia vs ezetimibe3 years

    Bempedoic Acid versus Ezetimibe and 3-Year Cardiovascular Outcomes in Statin-Intolerant Adults with Hyperlipidemia

    AHA Scientific Sessions 2026 abstract

Total major adverse cardiovascular events or major adverse limb events

downin humans1−19%

1 study
  1. Bempedoic acid decreases total major adverse cardiovascular events or major adverse limb events in humans (19%).

    “When we consider total, including recurrent, events, the composites of MACE-4+MALE and MACE-3+MALE were reduced by bempedoic acid by 19% (RR, 0.81 [95% CI, 0.73–0.89]; P<0.001) and 18% (RR, 0.82 [95% CI, 0.73–0.92]; P<0.001), respectively, with consistent effects, reaching statistical significance in those with and without PAD (Pinteraction=NS; Table S2”

    Human trialmedian of 40.6 monthsn = 13,970

    Bempedoic acid reduced leg complications in artery disease

    Circulation

  2. Bempedoic acid decreases total major adverse cardiovascular events or major adverse limb events in patients with peripheral artery disease (relative risk 0.71).

    “Total MACE-4 or MALE was reduced (relative risk, 0.81 [95% CI, 0.73-0.90]) overall with consistent effects in PAD (relative risk, 0.71 [95% CI, 0.54-0.95])”

    Human trialin patients with peripheral artery disease180 mg

    Bempedoic acid reduced leg complications in artery disease

    Circulation

Total major adverse limb events

downin humans1−45%

1 study
  1. Bempedoic acid decreases total major adverse limb events in patients with PAD (2.9 with bempedoic acid versus 4.0 with placebo).

    “Total, including recurrent, MALE were reduced with bempedoic acid (n/100 patient-years; 2.9 with bempedoic acid versus 4.0 with placebo; RR, 0.55 [95% CI, 0.35–0.85]; P=0.007; Table and Figure ).”

    Human trialin patients with PADmedian of 40.6 monthsn = 1,624

    Bempedoic acid reduced leg complications in artery disease

    Circulation

  2. Bempedoic acid decreases total major adverse limb events in patients with peripheral artery disease (-45%).

    “Bempedoic acid reduced total MALE by 45% (relative risk, 0.55 [95% CI, 0.35-0.85]; P=0.007).”

    Human trialin patients with peripheral artery disease180 mg

    Bempedoic acid reduced leg complications in artery disease

    Circulation

Lipids

downin humans1

1 study
  1. Bempedoic acid decreases lipids in humans (statin intolerance or unwillingness to take statins).

    “The CLEAR clinical trial series established BA's lipid-lowering effect and safety profile”

    Reviewstatin intolerance or unwillingness to take statins

    Bempedoic Acid in Statin-Intolerant Patients: Real-World Implementation Strategies, Cardiovascular Outcomes Beyond the CLEAR Trial, and Combination Therapy Approaches

    Current atherosclerosis reports

More on Lipids

Creatine kinase

upin humans1RR 1.13

1 study
  1. Bempedoic acid is linked with higher creatine kinase in humans (statin-intolerant hyperlipidemia vs ezetimibe) (10.4% vs 9.2%; RR 1.13, 1.07-1.20; P<0.001).

    “creatine kinase elevation (10.4% vs 9.2%; RR 1.13, 1.07-1.20; P<0.001)”

    Humansstatin-intolerant hyperlipidemia vs ezetimibe3 years

    Bempedoic Acid versus Ezetimibe and 3-Year Cardiovascular Outcomes in Statin-Intolerant Adults with Hyperlipidemia

    AHA Scientific Sessions 2026 abstract

More on Creatine kinase

New safety signals

no changein humans1

1 study
  1. Bempedoic acid was not clearly linked with new safety signals in humans across glycaemic subgroups.

    “No new safety signals were observed across the glycaemic subgroups.”

    Humansacross glycaemic subgroupsBA or BA + ezetimibe fixed dose combination1 year

    Bempedoic acid for LDL-cholesterol management in patients with and without diabetes: insights from the MILOS study

    ESC Congress 2026 abstract

Treatment discontinuation

upin humans1

1 study
  1. Bempedoic acid increases treatment discontinuation in humans.

    “treatment discontinuation was higher with bempedoic acid 180 mg and colesevelam 3.75 g”

    Human trial180 mg

    Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis

    Endocrinology, diabetes & metabolism

C-reactive protein

downin humans1

1 study
  1. Bempedoic acid decreases C-reactive protein in humans (-34.0% (p < 0.01)).

    “The median percentage changes from baseline to week 12 were -13.3% for non-high-density lipoprotein cholesterol (non-HDL-C), -10.8% for total cholesterol, -11.5% for apolipoprotein B, and -34.0% for hsCRP (all p < 0.01).”

    Human trial12 weeksn = 180

    Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients with Hypercholesterolemia - A Pragmatic Phase IV Study (CLEAR Taiwan Study)

    medRxivPreprint

More on C-reactive protein

Non-HDL cholesterol

downin humans1

1 study
  1. Bempedoic acid decreases non-HDL cholesterol in humans (added to background statin therapy, compared with placebo) (MD -15.50 mg/dL; 95% CI -18.95 to -12.04).

    “A pooled analysis showed a significant non-HDL-C reduction in the Bempedoic acid group compared to the placebo”

    Human trialadded to background statin therapy, compared with placebo12 weeksn = 3,034

    Efficacy of Bempedoic Acid Versus Placebo for Additional Lipid Lowering in Patients Receiving Background Statin Therapy: A Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

More on Non-HDL cholesterol

All 23

What is bempedoic acid linked with?

17

Studies link bempedoic acid with 17 measures, among them major adverse cardiovascular events, LDL cholesterol and major adverse cardiovascular events.

Major adverse cardiovascular events

downin humans2HR 0.86

2 studies
  1. Bempedoic acid lowers the risk of major adverse cardiovascular events in humans (monotherapy in statin-intolerant patients without baseline lipid lowering therapies) (-14% (HR 0.86, 95% CI 0.76-0.97)).

    “bempedoic acid monotherapy reduced MACE4 by 14% (HR 0.86; 95% CI, 0.76 – 0.97)”

    Human trialmonotherapy in statin-intolerant patients without baseline lipid lowering therapies180 mgn = 8,217

    Bempedoic acid monotherapy, LDL cholesterol and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial

    AHA Scientific Sessions 2025 abstract

  2. Bempedoic acid lowers the risk of major adverse cardiovascular events in humans (established ASCVD or high cardiovascular risk).

    “CLEAR Outcomes, which further demonstrated fewer major adverse cardiovascular events among patients with established ASCVD or at high cardiovascular risk.”

    Reviewestablished ASCVD or high cardiovascular risk

    Bempedoic Acid in Statin-Intolerant Patients: Real-World Implementation Strategies, Cardiovascular Outcomes Beyond the CLEAR Trial, and Combination Therapy Approaches

    Current atherosclerosis reports

LDL cholesterol

downin humans2

2 studies
  1. Bempedoic acid is associated with LDL cholesterol in humans (Change from baseline in statin-intolerant patients receiving GLP-1 receptor agonists) (16.8 mg/dL reduction from baseline; 113.2 to 96.4 mg/dL).

    “to 96.4 mg/dL in the bempedoic acid cohort (AR = 16.8 mg/dL)”

    HumansChange from baseline in statin-intolerant patients receiving GLP-1 receptor agonists1 yearn = 748

    Bempedoic Acid versus Ezetimibe for Secondary Prevention in Statin-Intolerant Patients with Cardiovascular-Kidney-Metabolic Syndrome Taking Glucagon-Like Peptide-1 Receptor Agonists

    AHA Scientific Sessions 2026 abstract

  2. Bempedoic acid is associated with LDL cholesterol in humans (hypercholesterolemia or mixed dyslipidemia; with or without other lipid-lowering therapies) (Mean relative reduction: 31.0% in women and 25.3% in men).

    “Bempedoic acid, with or without other LLTs, was associated with a >25% reduction in LDL-C in both sexes.”

    Humanshypercholesterolemia or mixed dyslipidemia; with or without other lipid-lowering therapiesalone or fixed-dose combination with ezetimibe1 yearn = 2,071

    Real-world use of bempedoic acid in women and men: pooled 1-year follow-up data from the observational, prospective, real-world MILOS study in Austria, Belgium, Germany, Italy, and the United Kingdom

    ESC Congress 2026 abstract

More on LDL cholesterol

Major adverse cardiovascular events

downin humans2RR 0.81–0.88

2 studies
  1. Bempedoic acid lowers the risk of major adverse cardiovascular events in humans (hypercholesterolemia) (RR 0.81 (95% CI 0.68–0.96)).

    “These changes translated into a 19 % relative reduction in MACE (RR 0.81, 95 % CI 0.68–0.96)”

    Human trialhypercholesterolemia

    Bempedoic Acid Lowers LDL-C and Reduces Risk of Major Cardiovascular Events in Hypercholesterolemia: Meta-Analysis of 13 Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

  2. Bempedoic acid is linked with a lower risk of major adverse cardiovascular events in humans (statin-intolerant hyperlipidemia vs ezetimibe) (10.8% vs 12.3%; RR 0.88, 0.83-0.92; HR 0.81, 0.76-0.85; P<0.001).

    “lower 3-point MACE (10.8% vs 12.3%; RR 0.88, 0.83-0.92; HR 0.81, 0.76-0.85; P<0.001)”

    Humansstatin-intolerant hyperlipidemia vs ezetimibe3 years

    Bempedoic Acid versus Ezetimibe and 3-Year Cardiovascular Outcomes in Statin-Intolerant Adults with Hyperlipidemia

    AHA Scientific Sessions 2026 abstract

More on Major adverse cardiovascular events

Major adverse cardiovascular events or major adverse limb events

downin humans1−13%HR 0.87

1 study
  1. Bempedoic acid lowers the risk of major adverse cardiovascular events or major adverse limb events in humans (HR, 0.87 [95% CI, 0.80–0.95]).

    “The composite of the trial primary outcome and MALE (MACE-4+MALE) was reduced overall with bempedoic acid (HR, 0.87 [95% CI, 0.80–0.95]; P=0.002; Table S3”

    Human trialmedian of 40.6 monthsn = 13,970

    Bempedoic acid reduced leg complications in artery disease

    Circulation

  2. Bempedoic acid lowers the risk of major adverse cardiovascular events or major adverse limb events in humans (-13%).

    “First MACE-4 or MALE was reduced overall by 13% (hazard ratio, 0.87 [95% CI, 0.80-0.95])”

    Human trial180 mg

    Bempedoic acid reduced leg complications in artery disease

    Circulation

Gout

upin humans1RR 1.21

1 study
  1. Bempedoic acid is linked with a higher risk of gout in humans (statin-intolerant hyperlipidemia vs ezetimibe) (3.7% vs 3.0%; RR 1.21, 1.09-1.34; HR 1.12, 1.01-1.24; P=0.040).

    “new or worsening gout (3.7% vs 3.0%; RR 1.21, 1.09-1.34; HR 1.12, 1.01-1.24; P=0.040)”

    Humansstatin-intolerant hyperlipidemia vs ezetimibe3 years

    Bempedoic Acid versus Ezetimibe and 3-Year Cardiovascular Outcomes in Statin-Intolerant Adults with Hyperlipidemia

    AHA Scientific Sessions 2026 abstract

More on Gout

3-point major adverse cardiovascular events

downin humans1HR 0.64

1 study
  1. Bempedoic acid lowers the risk of 3-point major adverse cardiovascular events in humans (High ASCVD risk; compared with no lipid-lowering therapy) (HR 0.64, 95% CI 0.48–0.85).

    “bempedoic acid (0.64, 0.48-0.85) and high-intensity statin (0.80, 0.69-0.92) reduced 3-point major adverse cardiovascular events (MACE) vs. no lipid-lowering therapy.”

    ReviewHigh ASCVD risk; compared with no lipid-lowering therapy

    Comparative effectiveness of lipid-lowering therapies for primary cardiovascular prevention: a network meta-analysis of randomised controlled trials

    EClinicalMedicine

Treatment discontinuation

upin humans1

1 study
  1. Bempedoic acid is associated with treatment discontinuation in humans (171/641 (26.7%)).

    “171/641 (26.7%) had discontinued bempedoic acid by follow-up.”

    Humansby follow-up, about 3 monthsn = 641

    Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study

    Lipids in health and disease

Suspected adverse events

upin humans1

1 study
  1. Bempedoic acid is associated with suspected adverse events in humans (218/641 (34.0%)).

    “Suspected adverse events were documented in 218/641 patients (34.0%)”

    Humansup to about 3 monthsn = 641

    Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study

    Lipids in health and disease

Myalgia

downin reviews1

1 study
  1. Bempedoic acid lowers the risk of myalgia (as reported in the cited network meta-analysis (Xie and colleagues)).

    “bempedoic acid ranks best for myalgia risk”

    Reviewas reported in the cited network meta-analysis (Xie and colleagues)

    Safety of lipid-lowering therapies: it is time for a "DOCebo" effect

    Nutrition, metabolism, and cardiovascular diseases : NMCD

More on Myalgia

Major adverse limb events

downin humans1−36%

1 study
  1. Bempedoic acid lowers the risk of major adverse limb events in patients with PAD (36%).

    “In patients with PAD, bempedoic acid reduced the risk of MALE by 36% (5.8% bempedoic acid versus 8.3% placebo; HR, 0.64 [95% CI, 0.44–0.93]; P=0.018; Table and Figure ), translating into an absolute risk reduction of 2.5% at a median of 40 months.”

    Human trialin patients with PADmedian of 40.6 monthsn = 1,624

    Bempedoic acid reduced leg complications in artery disease

    Circulation

More on Major adverse limb events

Major adverse limb events

downin humans1−36%

1 study
  1. Bempedoic acid lowers the risk of major adverse limb events in patients with peripheral artery disease (-36%).

    “Bempedoic acid reduced the risk of MALE by 36% (hazard ratio, 0.64 [95% CI, 0.44-0.93]; P=0.018).”

    Human trialin patients with peripheral artery disease180 mg

    Bempedoic acid reduced leg complications in artery disease

    Circulation

Hyperuricemia

upin humans1RR 1.93

1 study
  1. Bempedoic acid raises the risk of hyperuricemia in humans (hypercholesterolemia) (RR 1.93 (95% CI 1.75–2.14)).

    “hyperuricemia risk almost doubled with BA (RR 1.93, 95 % CI 1.75–2.14)”

    Human trialhypercholesterolemia

    Bempedoic Acid Lowers LDL-C and Reduces Risk of Major Cardiovascular Events in Hypercholesterolemia: Meta-Analysis of 13 Randomized Controlled Trials

    AHA Scientific Sessions 2025 abstract

More on Hyperuricemia

All 17

Has bempedoic acid been tested in people?

58 of 117 about aging

Yes: 7 trials and 22 observational studies in people have been published, and 32 trials are registered.

Approved

  • FDA Nexletol

    Feb 21, 2020Hypercholesterolemia, heterozygous familial hypercholesterolemia

  • EMA Nilemdo

    Apr 1, 2020Hypercholesterolemia, Dyslipidemias, Atherosclerotic Cardiovascular Disease, Hypercholesterolaemia, Mixed Dyslipidaemia

Repurposing

All 11

Every condition in trials

  • Hyperlipoproteinemia type II

    Phase 4Completed3 trials

  • Hyperlipidemias

    Phase 3Results posted7 trials

  • Hyper low density lipoprotein ldl cholesterolemia

    Phase 3Results posted2 trials

Readouts due

Who is developing bempedoic acid?

3 companies: Daiichi Sankyo, Esperion Therapeutics and Gan & Lee Pharmaceuticals..

Companies
  • Daiichi SankyoPhase 4primary hypercholesterolemia or mixed hyperlipidemia, coronary atherosclerosis
  • Esperion TherapeuticsPhase 4cardiovascular disease, statin adverse reaction
  • Gan & Lee Pharmaceuticals.Phase 3primary hyperlipidemia

Trial sponsors

Funding

1 grant since 2026

National Heart, Lung, and Blood Institute$581K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Reviews describe lower LDL-C and cardiovascular risk with bempedoic acid in high- and very-high-risk people unable or unwilling to take statins, but increased treatment discontinuation at 180 mg in people with dyslipidemia.

  2. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 8Feb 2026: 16Mar 2026: 3Apr 2026: 0May 2026: 3Jun 2026: 0Jul 2026: 2Aug 2026: 10Sep 2026: 6Oct 2026: 17Nov 2026: 1279 papers in 12 months

See all 98 papers on bempedoic acid